Patents Assigned to MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN BERLIN-BUCH
  • Peptides having binding affinity to an antibody which recognizes an epitope on an ?1 loop 2 or ?2 loop 1 of an adrenoreceptor
    Patent number: 9574017
    Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: February 21, 2017
    Assignees: MDC Max-Delbruck-Centrum Fur Molekulare Medizin Berlin-Buch, Fresenius Medical Care Deutschland GmbH
    Inventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube
  • Method for inhibiting cell death during liver failure by administering a caspase recruitment domain
    Patent number: 9474781
    Abstract: The invention refers to the use of a polynucleotide encoding “apoptosis repressor with caspase recruitment domain” (ARC) or a functional fragment thereof, and/or an ARC polypeptide or a functional fragment thereof for inhibiting cell death of a liver cell, in particular during liver failure.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: October 25, 2016
    Assignee: Max-Delbruck-Centrum Fur Molekulare Medizin Berlin-Buch
    Inventors: Stefan Donath, Junfeng An
  • Polynucleotides for medical use
    Patent number: 9115404
    Abstract: The invention pertains to a RNA molecule transcribed form a long terminal repeat (LTR) sequence, comprising a sequence encoding a gene, such as CSF1R, and a sequence that is at least in part found in the LTR, in particular for detecting cancer in a subject.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: August 25, 2015
    Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN BERLIN-BUCH
    Inventors: Stephan Mathas, Björn Lamprecht, Bernd Dörken, Constanze Bonifer
  • Polynucleotides for use in medicine
    Patent number: 9040238
    Abstract: The invention refers to polynucleotides selected from the group consisting of a) polynucleotides encoding for the polypeptide RBM20 comprising a P638L mutation for a human polypeptide RBM20, or a P641L mutation for a rat polypeptide RBM20, b) polynucleotides with a reverse complementary sequence of the polynucleotide of a) above, and c) polynucleotides with an identity at least 50% to a polynucleotide of a) or b) above.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: May 26, 2015
    Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN BERLIN-BUCH
    Inventors: Michael Gotthardt, Norbert Hübner, Marion Lewis Greaser, Wei Guo
  • GPNMB/OSTEOACTIVIN AS A BIOMARKER AND DRUG TARGET IN CARDIAC DISEASES
    Publication number: 20140031411
    Abstract: The present invention relates to the gene Gpnmb and its use as a genetic marker in the incidence of cardiovascular conditions and cardiac diseases, such as complications derived from myocardial infarction. Gpnmb provides a valuable tool both for diagnostic as well as therapeutic approaches, in order to treat or prevent cardiovascular conditions and cardiac diseases, in particular complications derived from myocardial infarction.
    Type: Application
    Filed: December 1, 2011
    Publication date: January 30, 2014
    Applicant: MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN BERLIN-BUCH
    Inventors: Michael Bader, Cemil Öczelik, Silke Mühlstedt
  • Peptides having binding affinity to an antibody which recognizes an epitope on an ?1 loop 2 or ?2 loop 1 of an adrenoreceptor
    Patent number: 8455442
    Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: June 4, 2013
    Assignees: MDC Max-Delbruck-Centrum fur Molekulare Medizin Berlin-Buch, Fresenius Medical Care Deutschland GmbH
    Inventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube